Heron Therapeutics (HRTX) just closed out FY 2025 with Q4 revenue of US$40.6 million and a basic EPS loss of US$0.02, alongside a trailing 12 month revenue base of US$154.9 million and a TTM basic EPS loss of US$0.12. Over recent quarters the company has seen revenue move between US$32.8 million and US$40.8 million, while quarterly basic EPS has ranged from a profit of US$0.02 to a loss of US$0.10. This gives investors a clearer view of how top line scale and per share results have been tracking into the latest print. With trailing 12 month net losses of US$20.2 million, the story here is still about how efficiently Heron can convert its revenue base into margins that support the growth narrative investors are watching.

See our full analysis for Heron Therapeutics.

With the latest numbers on the table, the next step is to see how this revenue and EPS profile lines up with the widely followed growth and profitability narratives around Heron, and where those stories might need updating.

TTM loss of US$20.2 million keeps profitability in focus

• On a trailing 12 month basis to Q4 FY 2025, Heron reported total revenue of US$154.9 million and a net loss of US$20.2 million, which works out to a basic EPS loss of US$0.12 over that period.
• Consensus narrative talks about earnings turning around over time, and these TTM numbers show the hurdle that view is working against.
  • Analysts in the balanced view are talking about margins eventually lifting from a current level described as around 0.6% loss to positive territory, while the latest TTM figures still show a multi million dollar annual loss.
  • That same narrative points to operational changes and financing as support for future earnings, yet the TTM loss of US$20.2 million and quarterly net income swinging between a US$3.0 million profit and a US$17.5 million loss highlight how dependent that view is on much steadier profitability than the recent record shows.

Quarterly swing from US$17.5 million loss to US$3.0 million loss

• Within FY 2025, net income moved from a loss of US$17.5 million in Q3 to a smaller loss of US$3.0 million in Q4, with revenue over those two quarters at US$38.2 million and US$40.6 million respectively, illustrating how sensitive results are to relatively modest shifts in sales and costs.
• Bulls argue that operational changes and payer tailwinds can turn this into a much more profitable business, and this pattern of swings gives you a sense of both the support and the challenge for that view.
  • The optimistic case talks about demand for non opioid therapies and policy support helping Heron grow revenue and margins, and the fact revenue has held in a band between about US$32.8 million and US$40.8 million per quarter gives that story a concrete revenue base to build from.
  • At the same time, the move from a US$17.5 million loss in Q3 to a smaller Q4 loss shows that changes in costs and mix can have a big impact on the bottom line in a short period, which bullish investors will watch closely as they think about earnings potential.

Have a closer look at how optimistic investors frame these swings in profitability and revenue against future expectations with the 🐂 Heron Therapeutics Bull Case.

Share dilution and ongoing losses worry cautious investors

• The trailing 12 month data shows Heron is still loss making with a net loss of US$20.2 million and TTM revenue of US$154.9 million, while analysis data flags that shareholders have also faced dilution over the past year.
• Bears focus on that combination of continuing losses and extra shares, and the figures here line up with several of their key concerns.
  • Cautious investors point to reliance on a small group of products and the need for external financing, and the fact that the company remains unprofitable on a TTM basis supports that focus on ongoing funding needs and potential future dilution.
  • They also highlight that cash burn and financing costs can weigh on EPS, and with basic EPS over the last four quarters ranging from a profit of US$0.02 to a loss of US$0.10, the data shows how fragile per share results can be when the share count rises and profitability is not yet established.

Skeptical investors are using this mix of dilution and losses as a key lens on the story, and you can see how they build that case in the 🐻 Heron Therapeutics Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Heron Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both the bullish and cautious angles, the real question is how this mix of risks and potential rewards sits with you. Move quickly, review the data, and shape your own stance by checking out 2 key rewards and 1 important warning sign.

See What Else Is Out There

Heron is still running at a TTM net loss of US$20.2 million, with ongoing share dilution and uneven EPS keeping profitability and per share outcomes under pressure.

If that mix of losses and dilution feels uncomfortable, you might want to check companies that score better on stability using our 80 resilient stocks with low risk scores to quickly spot alternatives with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.